Tag : high-efficacy solutions

Healthcare Quality, Patient Safety & Policy

Revolution, Summit to Test RAS(ON) Drugs with Ivonescimab

Business Wire
by Business Wire080
Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers and Summit Therapeutics Inc. (Nasdaq: SMMT), a...
Clinical Research, Pharma & Healthcare Financing

Dizal Completes Enrollment for Phase III Sunvozertinib NSCLC Study

PR Newswire
by PR Newswire098
Dizal announced the completion of patient enrollment for its WU-KONG28 clinical trial: a multinational, randomized phase III study evaluating the efficacy and safety of sunvozertinib versus...